Leerink Partnrs Comments on AstraZeneca Q2 Earnings

AstraZeneca PLC (NASDAQ:AZN) – Equities research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for AstraZeneca in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will earn $1.09 per share for the quarter. The consensus estimate for AstraZeneca’s current full-year earnings is $4.13 per share. Leerink Partnrs also issued estimates for AstraZeneca’s Q3 2025 earnings at $1.11 EPS.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%.

AZN has been the subject of several other reports. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Up 2.0 %

AZN opened at $72.36 on Friday. The firm has a 50 day simple moving average of $67.27 and a 200 day simple moving average of $73.70. The company has a market cap of $224.39 billion, a price-to-earnings ratio of 34.62, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46. AstraZeneca has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. McClarren Financial Advisors Inc. boosted its holdings in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. Capital Performance Advisors LLP bought a new stake in AstraZeneca in the 3rd quarter valued at $28,000. Albion Financial Group UT lifted its holdings in shares of AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock worth $40,000 after buying an additional 248 shares in the last quarter. Groupama Asset Managment boosted its position in shares of AstraZeneca by 22.9% in the third quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock valued at $42,000 after acquiring an additional 101,225 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in shares of AstraZeneca in the third quarter valued at about $45,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.